Skip to main content

Treatment Clinical Trials for Breast Cancer

Review the breast cancer treatment clinical trials on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 301-325 of 493

Postoperative Circulating Tumor Deoxyribonucleic Acid (ctDNA) Surveillance to Guide the Treatment of Early-Stage Triple Negative Breast Cancer Patients with Residual Disease, PREDICT-RD Trial
Status: Active
Location: UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina
Low or High Dose Radiation with Pembrolizumab and Preoperative Chemotherapy for the Treatment of Non-Metastatic Node Positive Triple Negative Breast Cancer, P-RAD(+)TN Trial
Status: Active
Location: UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina
Pembrolizumab Plus Combination Chemotherapy before Surgery for the Treatment of Stage I Triple Negative Breast Cancer
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Safety of Continuing HER-2 Directed Therapy in Overt Left Ventricular Dysfunction
Status: Active
Location: UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California
Trastuzumab, Pertuzumab and Docetaxel With or Without Carboplatin for the Treatment of Stage II-III HER2 Positive Breast Cancer, NeoTHERa Trial
Status: Active
Location: University of Kansas Cancer Center, Kansas City, Kansas
Hypofractionated Radiotherapy Before or After Breast Surgery for the Treatment of Patients with Non-Metastatic Breast Cancer
Status: Active
Location: 2 locations
Anthracycline-Free Chemotherapy and Immunotherapy Regimen for the Treatment of Triple-Negative Breast Cancer Patients at Risk for Cardiotoxicity, NeoCARD Trial
Status: Active
Location: Medical University of South Carolina, Charleston, South Carolina
Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)
Status: Active
Location: UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California
Evaluation of Immune Cells and Response-Adapted Chemoimmunotherapy before Surgery for the Treatment of Triple-Negative Breast Cancer, The NeoTRACT Trial
Status: Active
Location: University of Kansas Hospital-Westwood Cancer Center, Westwood, Kansas
177Lu-DOTATATE for the Treatment of Stage IV or Recurrent Breast Cancer
Status: Active
Location: OHSU Knight Cancer Institute, Portland, Oregon
Tamoxifen Citrate or Aromatase Inhibitor in Treating Elderly Patients with Estrogen Receptor Positive Breast Cancer That Can Be Removed by Surgery
Status: Active
Location: Siteman Cancer Center at Washington University, Saint Louis, Missouri
Reduced Adjuvant Systemic Therapy for the Treatment of Patients with Early Breast Cancer Who Experienced a Pathological Complete Response After Neoadjuvant Systemic Therapy and Do Not Have Molecular Residual Disease, MolecularPCR Trial
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
A Vaccine (Dendritic Cell 1) for the Treatment of Patients with HER-2 Positive Breast Cancer, NATASHA Study
Status: Active
Location: Moffitt Cancer Center, Tampa, Florida
Darolutamide Alone or in Combination with Standard Therapy before Surgery for the Treatment of Stage II-IIIA, Androgen Receptor Positive, Triple-Negative Breast Carcinoma
Status: Active
Location: Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee
Neoadjuvant Neratinib for the Treatment of Stage I-III HER2-Mutated Lobular Breast Cancers
Status: Active
Location: Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee
Leuprolide and Goserelin for Ovarian Function Suppression in Pre- or Peri-menopausal Women with Breast Cancer, OFS Trial
Status: Active
Location: University of Michigan Rogel Cancer Center, Ann Arbor, Michigan
Comparison of Adjuvant Endocrine Therapy and Accelerated Partial Breast Irradiation following Lumpectomy for the Treatment of Early-Stage Breast Cancer Patients Over 65, CAMERAN Study
Status: Active
Location: UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina
Palbociclib and Pembrolizumab for the Treatment of Patients with Brain Metastases
Status: Active
Location: Massachusetts General Hospital Cancer Center, Boston, Massachusetts
Radiation Therapy without Endocrine Therapy for Treatment in Older Patients with Stage IA-IB Estrogen Receptor Positive Breast Cancer, EMERALD Trial
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Zanidatamab before Surgery for the Treatment of Early Stage HER2/Neu Positive Breast Cancer
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Circulating Tumor DNA to Guide Changes in Standard of Care Chemotherapy in Patients with Metastatic Triple Negative Breast Cancer
Status: Active
Location: Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee
A Vaccine (STEMVAC) with Standard Endocrine-Based Therapy or Chemotherapy for the Treatment of Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer
Status: Active
Location: Fred Hutch/University of Washington/Seattle Children's Cancer Consortium, Seattle, Washington
A Sequential Treatment Plan for the Treatment of Hormone Positive Metastatic Breast Cancer
Status: Active
Location: Moffitt Cancer Center, Tampa, Florida
Magtrace for Delayed Sentinel Lymph Node Biopsy in Patients with Ductal Carcinoma In-Situ
Status: Active
Location: UF Health Cancer Institute - Gainesville, Gainesville, Florida
Adaptive Therapy with Capecitabine for the Treatment of Metastatic Estrogen Receptor Positive, HER2 Negative Breast Cancer
Status: Active
Location: Mayo Clinic in Arizona, Scottsdale, Arizona